成人血流感染抗菌治疗临床试验主要终点的共识定义
该共识通过改良德尔菲法,基于2005至2016年比较血流感染抗菌治疗的研究,为 pilot 和确定性试验分别定义了针对金黄色葡萄球菌和革兰阴性菌血流感染的主要和次要终点,以标准化未来试验设计。
要点
- 金黄色葡萄球菌血流感染 pilot 试验主要终点为第7天成功,确定性试验为第90天成功。
- 革兰阴性菌血流感染 pilot 试验主要终点为第7天成功,确定性试验主要终点为第90天生存。
- 这些终点需进一步验证与以患者为中心的临床结局的关系。
核心结论
- 共识定义了成人血流感染抗菌治疗临床试验的标准化主要和次要终点,供未来试验设计使用。
研究设计与样本
- 通过改良德尔菲法,基于2005至2016年发表的前瞻性研究、随机试验或注册方案制定共识终点。
主要发现
- 针对 pilot 试验和确定性试验,以及金黄色葡萄球菌和革兰阴性菌血流感染,分别定义了不同的主要和次要终点。
关键数值与推荐
- 金黄色葡萄球菌血流感染 pilot 试验主要终点为第7天成功:生存、发热消退、SOFA评分稳定或改善、血培养清除,且至90天无微生物学确认的失败。
- 金黄色葡萄球菌血流感染确定性试验主要终点为第90天成功:生存且无微生物学确认的失败。
- 革兰阴性菌血流感染 pilot 试验主要终点为第7天成功:生存、发热及感染源相关症状消退、SOFA评分稳定或改善、血培养阴性。
- 革兰阴性菌血流感染确定性试验主要终点为第90天生存,次要终点为第7天成功(定义同上)。
临床怎么用
- 临床医生可参考这些共识终点理解血流感染抗菌治疗试验的设计与结果解读。
局限性
- 这些终点需进一步验证与以患者为中心的临床结局的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI). METHODS: Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. RESULTS: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. CONCLUSIONS: These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes.
引用
- Harris PNA, McNamara JF, Lye DC, et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clin Microbiol Infect. 2016. PMID: 27810466. doi:10.1016/j.cmi.2016.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。